1-Sulfonylindazoles as potent and selective 5-HT6 ligands

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 9, 2009, Pages 2413-2415

  Liu, Kevin G ^a   Lo, Jennifer R ^a   Comery, Thomas A ^a   Zhang, Guo Ming ^a   Zhang, Jean Y ^a   Kowal, Dianne M ^a   Smith, Deborah L ^a   Di, Li ^a   Kerns, Edward H ^a   Schechter, Lee E ^a   Robichaud, Albert J ^a  

^a PFIZER INC   (United States)

Author keywords

5 HT; 5 HT6; 5 Hydroxytraptamine; 5 Hydroxytryptamine 6; Alzheimer's disease; Cognition; Cognitive dysfunction; Cognitive impairment; Schizophrenia; Serotonin

Indexed keywords

CYTOCHROME P450; INDAZOLE DERIVATIVE; SEROTONIN 6 ANTAGONIST; SEROTONIN 6 RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; COGNITIVE DEFECT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; ENZYME INHIBITION; IN VIVO STUDY; MALE; NONHUMAN; RAT; RECEPTOR BLOCKING; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CENTRAL NERVOUS SYSTEM DISEASES; COGNITION DISORDERS; DRUG DESIGN; HUMANS; INDAZOLES; INHIBITORY CONCENTRATION 50; KINETICS; LIGANDS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN;

RATTUS;

EID: 64249100991     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.03.071     Document Type: Article

References (19)

1. Peuskens J., Demily C., and Thibaut F. Clin. Ther. 27 (2005) S25
2. Bowie Christopher R., and Jaga K. Expert. Rev. Neurother. 7 (2007) 281
3. Kuperberg G., and Heckers S. Curr. Opin. Neurobiol. 10 (2000) 205
4. Galletly C.A., Clark C.R., and MacFarlane A.C. J. Psychiatry Neurosci. 25 (2000) 117
5. Robichaud A.J. Curr. Top. Med. Chem. 6 (2006) 553
6. Monsma Jr. F.J., Shen Y., Ward R.P., Hamblin M.W., and Sibley D.R. Mol. Pharmacol. 43 (1993) 320
7. Ruat M., Traiffort E., Arrang J.M., Tardivel-Lacombe J., Diaz J., Leurs R., and Schwartz J.C. Biochem. Biophys. Res. Commun. 193 (1993) 268
8. Woolley M.L., Marsden C.A., and Fone K.C.F. Curr. Drug Targets CNS Neurol. Disord. 3 (2004) 59
9. Glennon R.A. J. Med. Chem. 46 (2003) 2795
10. Holenz J., Pauwels P.J., Diaz J.L., Merce R., Codony X., and Buschmann H. Drug Discov. Today 11 (2006) 283
11. Liu, K. G.; Robichaud, A. J. Drug Develop. Res. 2009, 70, 145.
12. Liu K.G., Lo J.R., Comery T.A., Zhang G.M., Zhang J.Y., Kowal D.M., Smith D.L., Di L., Kerns E.H., Schechter L.E., and Robichaud A.J. Bioorg. Med. Chem. Lett. 18 (2008) 3929
13. Liu K.G., Lo J.R., Comery T.A., Zhang G.M., Zhang J.Y., Kowal D.M., Smith D.L., Di L., Kerns E.H., Schechter L.E., and Robichaud A.J. Bioorg. Med. Chem. Lett. 19 (2009) 1115
14. Cole D.C., Lennox W.J., Lombardi S., Ellingboe J.W., Bernotas R.C., Tawa G.J., Mazandarani H., Smith D.L., Zhang G., Coupet J., and Schechter L.E. J. Med. Chem. 48 (2005) 353
15. Kaumann A.J., and Levy F.O. Pharmacol. Ther. 111 (2006) 674
16. Porter R.H.P., Benwell K.R., Lamb H., Malcolm C.S., Allen N.H., Revell D.F., Adams D.R., and Sheardown M.J. Br. J. Pharmacol. 128 (1999) 13
17. Winters B.D., Saksida L.M., and Bussey T. J. Neurosci. Biobehav. Rev. 32 (2008) 1055
18. Di L., Kerns E., Li S., and Petusky S. Int. J. Pharm. 317 (2006) 54
19. Di L., Kerns E., McConnell O., and Carter G. Eur. J. Med. Chem. 38 (2003) 223